HighTower Advisors LLC decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE – Free Report) by 92.1% in the 4th quarter, HoldingsChannel.com reports. The firm owned 523,599 shares of the company’s stock after selling 6,136,004 shares during the period. HighTower Advisors LLC’s holdings in Kenvue were worth $9,032,000 at the end of the most recent reporting period.
Several other large investors also recently made changes to their positions in the business. Intrua Financial LLC boosted its position in shares of Kenvue by 6.5% during the 4th quarter. Intrua Financial LLC now owns 19,825 shares of the company’s stock valued at $342,000 after purchasing an additional 1,205 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. bought a new position in shares of Kenvue during the 4th quarter valued at about $7,227,000. Gabelli Funds LLC bought a new position in shares of Kenvue during the 4th quarter valued at about $7,302,000. North Dakota State Investment Board bought a new position in shares of Kenvue during the 4th quarter valued at about $1,124,000. Finally, Elyxium Wealth LLC bought a new position in shares of Kenvue during the 4th quarter valued at about $26,000. Institutional investors own 97.64% of the company’s stock.
Kenvue Stock Performance
Shares of KVUE opened at $17.55 on Tuesday. Kenvue Inc. has a one year low of $14.02 and a one year high of $24.00. The company has a 50-day moving average of $17.41 and a two-hundred day moving average of $17.44. The stock has a market cap of $33.69 billion, a price-to-earnings ratio of 20.64, a PEG ratio of 1.33 and a beta of 0.55. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70.
Kenvue Dividend Announcement
The business also recently declared a quarterly dividend, which will be paid on Wednesday, May 27th. Stockholders of record on Wednesday, May 13th will be given a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.7%. The ex-dividend date of this dividend is Wednesday, May 13th. Kenvue’s dividend payout ratio is 97.65%.
Analysts Set New Price Targets
Several research firms have recently weighed in on KVUE. UBS Group reduced their price objective on shares of Kenvue from $19.00 to $18.00 and set a “neutral” rating for the company in a research report on Tuesday, April 7th. Zacks Research upgraded shares of Kenvue from a “hold” rating to a “strong-buy” rating in a research report on Friday, May 8th. Barclays decreased their target price on shares of Kenvue from $19.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, April 14th. Canaccord Genuity Group raised their target price on shares of Kenvue from $17.00 to $18.00 and gave the stock a “hold” rating in a report on Wednesday, February 18th. Finally, Jefferies Financial Group cut shares of Kenvue from a “buy” rating to a “hold” rating and decreased their target price for the stock from $23.00 to $18.00 in a report on Friday, January 30th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and twelve have given a Hold rating to the company’s stock. According to MarketBeat.com, Kenvue has a consensus rating of “Hold” and an average price target of $19.33.
Get Our Latest Research Report on KVUE
Insider Activity
In other news, General Counsel Matthew Orlando sold 38,491 shares of the stock in a transaction that occurred on Friday, May 8th. The shares were sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 1.59% of the stock is owned by company insiders.
About Kenvue
Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over?the?counter medicines.
The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.
Further Reading
- Five stocks we like better than Kenvue
- SpaceX Gets the Attention, But These 4 Stocks Could Get the Returns
- Microsoft Stock Discount May Be Ending as AI Catalysts Build
- Apparel Earnings Winners and Losers: Ralph Lauren Takes Off
- Why Walmart, Target and TJX Got Such Different Reactions After Earnings
Want to see what other hedge funds are holding KVUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Kenvue Inc. (NYSE:KVUE – Free Report).
Receive News & Ratings for Kenvue Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kenvue and related companies with MarketBeat.com's FREE daily email newsletter.
